These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 25295194)

  • 1. The RAG Model: A New Paradigm for Genetic Risk Stratification in Multiple Myeloma.
    Prideaux SM; Conway O'Brien E; Chevassut TJ
    Bone Marrow Res; 2014; 2014():526568. PubMed ID: 25295194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Still high risk? A review of translocation t(14;16) in multiple myeloma.
    Mian H; Kaiser M; Fonseca R
    Am J Hematol; 2024 Jun; ():. PubMed ID: 38874195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erratum to: Comprehensive analysis and establishment of a prognostic model based on non-genetic predictors in multiple myeloma.
    Cancer Biomark; 2023; 38(3):411. PubMed ID: 37781793
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease.
    Kortüm KM; Langer C; Monge J; Bruins L; Egan JB; Zhu YX; Shi CX; Jedlowski P; Schmidt J; Ojha J; Bullinger L; Liebisch P; Kull M; Champion MD; Van Wier S; Ahmann G; Rasche L; Knop S; Fonseca R; Einsele H; Stewart AK; Braggio E
    Br J Haematol; 2015 Feb; 168(4):507-10. PubMed ID: 25302557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors.
    Tornatore L; Sandomenico A; Raimondo D; Low C; Rocci A; Tralau-Stewart C; Capece D; D'Andrea D; Bua M; Boyle E; van Duin M; Zoppoli P; Jaxa-Chamiec A; Thotakura AK; Dyson J; Walker BA; Leonardi A; Chambery A; Driessen C; Sonneveld P; Morgan G; Palumbo A; Tramontano A; Rahemtulla A; Ruvo M; Franzoso G
    Cancer Cell; 2014 Oct; 26(4):495-508. PubMed ID: 25314077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How I treat smoldering multiple myeloma.
    Ghobrial IM; Landgren O
    Blood; 2014 Nov; 124(23):3380-8. PubMed ID: 25298034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential.
    Paíno T; Paiva B; Sayagués JM; Mota I; Carvalheiro T; Corchete LA; Aires-Mejía I; Pérez JJ; Sanchez ML; Barcena P; Ocio EM; San-Segundo L; Sarasquete ME; García-Sanz R; Vidriales MB; Oriol A; Hernández MT; Echeveste MA; Paiva A; Blade J; Lahuerta JJ; Orfao A; Mateos MV; Gutiérrez NC; San-Miguel JF
    Leukemia; 2015 May; 29(5):1186-94. PubMed ID: 25388955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma.
    Paiva B; Chandia M; Puig N; Vidriales MB; Perez JJ; Lopez-Corral L; Ocio EM; Garcia-Sanz R; Gutierrez NC; Jimenez-Ubieto A; Lahuerta JJ; Mateos MV; San Miguel JF
    Haematologica; 2015 Feb; 100(2):e53-5. PubMed ID: 25381128
    [No Abstract]   [Full Text] [Related]  

  • 9. Haematological cancer: Optimizing the treatment of multiple myeloma.
    Morgan GJ; van Rhee F
    Nat Rev Clin Oncol; 2014 Dec; 11(12):686-8. PubMed ID: 25348792
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma.
    Silvennoinen R; Lundan T; Kairisto V; Pelliniemi TT; Putkonen M; Anttila P; Huotari V; Mäntymaa P; Siitonen S; Uotila L; Penttilä TL; Juvonen V; Selander T; Remes K
    Blood Cancer J; 2014 Oct; 4(10):e250. PubMed ID: 25303369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment.
    Pawlyn C; Khan MS; Muls A; Sriskandarajah P; Kaiser MF; Davies FE; Morgan GJ; Andreyev HJ
    Blood; 2014 Oct; 124(15):2467-8. PubMed ID: 25301337
    [No Abstract]   [Full Text] [Related]  

  • 12. RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2.
    Zhu YX; Yin H; Bruins LA; Shi CX; Jedlowski P; Aziz M; Sereduk C; Kortuem KM; Schmidt JE; Champion M; Braggio E; Keith Stewart A
    Blood; 2015 Jan; 125(3):483-91. PubMed ID: 25395420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GP130 activation induces myeloma and collaborates with MYC.
    Dechow T; Steidle S; Götze KS; Rudelius M; Behnke K; Pechloff K; Kratzat S; Bullinger L; Fend F; Soberon V; Mitova N; Li Z; Thaler M; Bauer J; Pietschmann E; Albers C; Grundler R; Schmidt-Supprian M; Ruland J; Peschel C; Duyster J; Rose-John S; Bassermann F; Keller U
    J Clin Invest; 2014 Dec; 124(12):5263-74. PubMed ID: 25384216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical course and prognosis of non-secretory multiple myeloma.
    Chawla SS; Kumar SK; Dispenzieri A; Greenberg AJ; Larson DR; Kyle RA; Lacy MQ; Gertz MA; Rajkumar SV
    Eur J Haematol; 2015 Jul; 95(1):57-64. PubMed ID: 25382589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How I treat relapsed myeloma.
    Bladé J; Rosiñol L; Fernández de Larrea C
    Blood; 2015 Mar; 125(10):1532-40. PubMed ID: 25587037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoglobulin Free Light Chains and GAGs Mediate Multiple Myeloma Extracellular Vesicles Uptake and Secondary NfκB Nuclear Translocation.
    Di Noto G; Chiarini M; Paolini L; Mazzoldi EL; Giustini V; Radeghieri A; Caimi L; Ricotta D
    Front Immunol; 2014; 5():517. PubMed ID: 25386176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classifying ultra-high risk smoldering myeloma.
    Waxman AJ; Mick R; Garfall AL; Cohen A; Vogl DT; Stadtmauer EA; Weiss BM
    Leukemia; 2015 Mar; 29(3):751-3. PubMed ID: 25371175
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of bendamustine in the management of plasma cell myeloma.
    Gertz MA
    Leuk Lymphoma; 2015 May; 56(5):1195-6. PubMed ID: 25347428
    [No Abstract]   [Full Text] [Related]  

  • 19. Overcoming multiple myeloma drug resistance in the era of cancer 'omics'.
    Guang MHZ; McCann A; Bianchi G; Zhang L; Dowling P; Bazou D; O'Gorman P; Anderson KC
    Leuk Lymphoma; 2018 Mar; 59(3):542-561. PubMed ID: 28610537
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.